

Supporting Information

Organophotoredox-Catalyzed C(sp²)-N Cross Coupling Reaction of Cyclic Aldimines with Cyclic Aliphatic Amines

Xue Liu,^a Jingjing Wang,^{*b} Ziyan Wu,^b Feng Li,^b Kexin Gao,^b Fanyang Peng,^b Junjie

Wang,^b Renzeng Shen,^b Yao Zhou,^{*c} and Lantao Liu^{*a,b}

^a College of Chemistry, Zhengzhou University, Zhengzhou, Henan, 450052, China

^b Henan Engineering Laboratory of Green Synthesis for Pharmaceuticals, College of Chemistry and Chemical Engineering, Shangqiu Normal University, Shangqiu, Henan, 476000, China

^c College of Chemistry and Chemical Engineering, Hubei Normal University, Huangshi, Hubei, 435002, China

E-mail: wangjingjing0918@163.com or yaozhou@hbnu.edu.cn or liult05@iccas.ac.cn

Table of Contents


| | |
|-------------------------------|-------|
| Experimental Section | 1–14 |
| Copies of NMR Spectra | 15–43 |
| Crystallographic data for 3aa | 44–45 |

General information:


^1H , and ^{13}C were recorded at Bruker 400 MHz (^1H NMR) and 100 MHz (^{13}C NMR). Chemical shifts were reported in ppm from the solvent resonance as the internal standard (CDCl_3 : 7.26 ppm, 77.0 ppm). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), br (broad). Coupling constants were reported in Hertz (Hz). Infrared spectra were obtained with a AVATAR 360 FT-IR spectrometer. Melting points were measured with a XT-4 melting point apparatus without correction. X-ray structural analysis was conducted on the XtaLAB mini. The high resolution ESI-MS spectra were obtained with a Bruker APEX IV Fourier transformmass spectrometer.

Materials: All commercially available reagents and solvent were used without further purification. Analytical thin layer chromatography was performed on 0.25 mm silica gel plates. Silica gel (200-300 mesh) was used for flash chromatography. Cyclic N -sulfimines were prepared according to the literatures.^[1]

The photos of the reaction set-up:




General Procedure for the visible light-induced organophotocatalyzed $\text{C}(\text{sp}^2)\text{-N}$ Cross Coupling Reactions of Cyclic Aldimines with Cyclic Aliphatic Amines:




To a 15 mL Schlenk charged with cyclic aldimines **1** (0.2 mmol), Eosin Y (6.5 mg, 0.01 mmol), DABCO (45 mg, 0.4 mmol) and cyclic aliphatic amines **2** (0.4 mmol) was added DMSO (2.0 mL) *via* a syringe. Then, the reaction mixture was open to the air and vigorously stirred under the irradiation of 23 W white LEDs at room temperature for 24 h. After the reaction was complete, the mixture was diluted with water (10 mL) and ethyl acetate (10 mL). The organic layer was washed with saturated brine (3×10 mL), dried anhydrous MgSO_4 , and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (petroleum ether/EtOAc as the eluent) to afford the desired products **3**.

4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3aa):



83% yield, mp 192–193 °C; **1H NMR** (400 MHz, CDCl_3) δ 3.81–3.84 (m, 4H), 3.87–3.89 (m, 4H), 7.33 (t, $J = 7.6$ Hz, 1H), 7.36 (d, $J = 8.0$ Hz, 1H), 7.54 (dd, $J = 8.0$ Hz, 1.2 Hz, 1H), 7.64 (dt, $J = 8.4$ Hz, 1.2 Hz, 1H); **13C NMR** (100 MHz, CDCl_3) δ 163.1, 154.5, 135.3, 128.0, 124.8, 120.7, 112.8, 66.4, 49.1; **IR** (KBr) ν 2923, 2862, 1588, 1538, 1359, 1197, 1114, 1027, 878 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 269.0591, found 269.0977.


8-methyl-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ba):



65% yield, mp 172–173 °C; **1H NMR** (400 MHz, CDCl_3) δ 2.37 (s, 3H), 3.78–3.80


(m, 4H), 3.83–3.86 (m, 4H), 7.20 (t, J = 7.6 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H); **^{13}C NMR** (100 MHz, CDCl_3) δ 163.6, 152.6, 136.5, 130.3, 125.5, 124.1, 112.4, 66.3, 49.2, 15.2; **IR** (KBr) ν 2922, 2861, 1594, 1539, 1444, 1361, 1275, 1159, 1116, 879 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 283.0747, found 283.1131.

7-methyl-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ca):




73% yield, mp 210–211 °C; **^1H NMR** (400 MHz, CDCl_3) δ 2.44 (s, 3H), 3.79–3.81 (m, 4H), 3.84–3.86 (m, 4H), 7.11 (d, J = 8.4 Hz, 1H), 7.14 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H); **^{13}C NMR** (100 MHz, CDCl_3) δ 163.1, 154.4, 147.3, 127.8, 125.8, 120.7, 110.1, 66.3, 49.1, 21.7; **IR** (KBr) ν 2922, 2862, 1618, 1579, 1528, 1450, 1355, 1269, 1168, 1109, 1029, 946, 865 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 283.0747, found 283.1131.

6-methyl-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3da):




58% yield, mp 224–225 °C; **^1H NMR** (400 MHz, CDCl_3) δ 2.42 (s, 3H), 3.82–3.85 (m, 4H), 3.88–3.91 (m, 4H), 7.28 (s, 1H), 7.82 (d, J = 1.2 Hz, 1H), 7.46 (dd, J = 8.4 Hz, 2.0 Hz, 1H); **^{13}C NMR** (100 MHz, CDCl_3) δ 163.2, 152.4, 136.1, 134.8, 127.9, 120.4, 112.5, 66.4, 49.1, 21.0; **IR** (KBr) ν 2920, 2861, 1539, 1482, 1357, 1270, 1168, 1114, 881, 830 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 283.0747, found 283.1131.

6-ethyl-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ea):




63% yield, mp 167–168 °C; **1H NMR** (400 MHz, CDCl_3) δ 1.25 (d, $J = 7.6$ Hz, 3H), 2.69 (q, $J = 7.6$ Hz, 2H), 3.80–3.83 (m, 4H), 3.86–3.89 (m, 4H), 7.26 (d, $J = 8.4$ Hz, 1H), 7.32 (d, $J = 2.0$ Hz, 1H), 7.46 (dd, $J = 8.4$ Hz, 2.0 Hz, 1H); **13C NMR** (100 MHz, CDCl_3) δ 163.3, 152.4, 141.0, 135.0, 126.8, 120.4, 112.5, 66.3, 49.1, 28.2, 15.3; **IR** (KBr) ν 2975, 2922, 1590, 1538, 1452, 1359, 1272, 1190, 1108, 1028, 880 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 297.0904, found 297.1301.

6-(tert-butyl)-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3fa):



81% yield, mp 246–247 °C; **1H NMR** (400 MHz, CDCl_3) δ 1.33 (s, 9H), 3.82–3.85 (m, 4H), 3.86–3.89 (m, 4H), 7.28 (d, $J = 8.8$ Hz, 1H), 7.49 (d, $J = 2.4$ Hz, 1H), 7.67 (dd, $J = 8.4$ Hz, 2.0 Hz, 1H); **13C NMR** (100 MHz, CDCl_3) δ 163.6, 152.2, 148.0, 132.8, 124.6, 120.0, 111.9, 66.4, 49.3, 34.7, 31.1; **IR** (KBr) ν 2921, 2863, 1637, 1539, 1364, 1266, 1196, 1116, 1028, 883 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{15}\text{H}_{21}\text{N}_2\text{O}_4\text{S}$ [$\text{M}+\text{H}]^+$ 325.1217, found 325.1642.


6-methoxy-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ga):



55% yield, mp 203–204 °C; **1H NMR** (400 MHz, CDCl_3) δ 3.80–3.84 (m, 7H), 3.87–3.90 (m, 4H), 6.98 (d, $J = 3.2$ Hz, 1H), 7.17 (dd, $J = 8.4$ Hz, 2.8 Hz, 1H), 7.30 (d, $J = 9.2$ Hz, 1H); **13C NMR** (100 MHz, CDCl_3) δ 163.1, 156.0, 147.9, 121.5, 120.5, 113.2, 113.0, 66.3, 56.0, 49.1; **IR** (KBr) ν 2921, 2820, 1622, 1543, 1486, 1343, 1275, 1166,


1025, 830, 750 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_5\text{S} [\text{M}+\text{H}]^+$ 299.0696, found 299.1113.

4-morpholino-6-phenylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ha):




38% yield, mp 219–220 $^\circ\text{C}$; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 3.82–3.86 (m, 4H), 3.89–3.94 (m, 4H), 7.41–7.46 (m, 2H), 7.47–7.51 (m, 4H), 6.67 (d, $J = 2.0$ Hz, 1H), 7.83 (dd, $J = 8.4$ Hz, 2.4 Hz, 1H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 163.1, 153.6, 138.6, 138.5, 134.1, 129.2, 128.4, 126.9, 126.4, 121.0, 113.0, 66.4, 49.0; **IR** (KBr) ν 2920, 2823, 1645, 1542, 1470, 1362, 1195, 1114, 1026, 879 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_4\text{S} [\text{M}+\text{H}]^+$ 345.0904, found 345.1356.

6-chloro-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ia):



65% yield, mp 197–198 $^\circ\text{C}$; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 3.16–3.18 (m, 4H), 3.76–3.79 (m, 4H), 6.74 (d, $J = 8.4$ Hz, 1H), 7.12 (d, $J = 2.4$ Hz, 1H), 7.18 (dd, $J = 8.4$ Hz, 2.4 Hz, 1H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 163.2, 151.3, 131.7, 127.8, 125.7, 121.6, 119.6, 66.0, 49.6; **IR** (KBr) ν 2923, 2821, 1632, 1542, 1469, 1128, 1110, 870 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{11}\text{H}_{12}\text{ClN}_2\text{O}_4\text{S} [\text{M}+\text{H}]^+$ 303.0201, found 303.0604.


7-chloro-4-morpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ja):



72% yield, mp 244–245 $^\circ\text{C}$; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 3.81–3.84 (m, 4H), 3.85–3.88 (m, 4H), 7.30 (dd, 8.4 Hz, 2.0 Hz, 1H), 7.38 (d, $J = 2.0$ Hz, 1H), 7.47 (d, $J = 8.8$


Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 162.3, 155.0, 141.4, 128.8, 125.4, 121.1, 111.3, 66.3, 49.2; **IR** (KBr) ν 2922, 2821, 1604, 1579, 1532, 1461, 1363, 1196, 1114, 868 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₂ClN₂O₄S [M+H]⁺ 303.0201, found 303.0604.

4-thiomorpholinobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ab):




65% yield, mp 203–204 °C; **¹H NMR** (400 MHz, CDCl₃) δ 2.81–2.84 (m, 4H), 4.07–4.10 (m, 4H), 7.31–7.37 (m, 2H), 7.52 (dd, 8.0 Hz, 1.2 Hz, 1H), 7.64 (dt, 8.8 Hz, 2.0 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 163.7, 154.5, 135.3, 127.9, 124.9, 120.7, 113.0, 51.4, 27.3; **IR** (KBr) ν 2920, 2820, 1610, 1587, 1532, 1467, 1360, 1259, 1188, 955, 863 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₃N₂O₃S₂ [M+H]⁺ 285.0362, found 285.0749.

4-(1,1-dioxidothiomorpholino)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3ac):



85% yield, mp 252–253 °C; **¹H NMR** (400 MHz, DMSO-d₆) δ 3.40–3.53 (m, 4H), 4.07–4.21 (m, 4H), 7.47 (t, 8.0 Hz, 1H), 7.57 (d, 8.4 Hz, 1H), 7.80 (dt, 8.4 Hz, 1.2 Hz, 1H), 7.86 (dd, 8.0 Hz, 1.2 Hz, 1H); **¹³C NMR** (100 MHz, DMSO-d₆) δ 163.3, 153.3, 135.9, 129.1, 125.5, 119.9, 112.7, 50.3, 46.6; **IR** (KBr) ν 2923, 2820, 1583, 1523, 1452, 1362, 1190, 1124, 1040, 953, 753 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₃N₂O₅S₂ [M+H]⁺ 317.0260, found 317.0691.


4-(piperidin-1-yl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3ad):



45% yield, mp 127–128 °C; **¹H NMR** (400 MHz, CDCl₃) δ 1.70–1.81 (m, 6H), 3.71–


3.82 (m, 4H), 7.28–7.33 (m, 2H), 7.86 (dd, 8.0 Hz, 2.0 Hz, 1H), 7.60 (dt, 8.8 Hz, 1.6 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 162.6, 154.3, 134.9, 128.2, 120.4, 49.6, 25.8, 24.0; **IR** (KBr) ν 2928, 2826, 1637, 1585, 1539, 1467, 1356, 1265, 1185, 1099, 869, 750 cm⁻¹; **HRMS** (ESI): calcd for C₁₂H₁₅N₂O₃S [M+H]⁺ 267.0798, found 267.1150.

4-(4-(trifluoromethyl)piperidin-1-yl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3ae):




85% yield, mp 201–202 °C; **¹H NMR** (400 MHz, CDCl₃) δ 1.73–1.84 (m, 2H), 2.07 (d, 12.8 Hz, 2H), 1.37–2.51 (m, 1H), 3.18 (t, 12.8 Hz, 2H), 4.50 (d, 13.2 Hz, 2H), 7.32–7.37 (m, 2H), 7.54 (d, 7.6 Hz, 1H), 7.65 (t, 7.2 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 163.5, 154.4, 135.4, 128.0, 126.6 (q, J_{C-F} = 276.7 Hz), 124.9, 120.6, 112.9, 47.7, 40.1 (q, J_{C-F} = 27.9 Hz), 24.4; **IR** (KBr) ν 2918, 2819, 1611, 1588, 1537, 1470, 1363, 1210, 1105, 866, 747 cm⁻¹; **HRMS** (ESI): calcd for C₁₃H₁₄F₃N₂O₃S [M+H]⁺ 335.0672, found 335.1115.

1-(2,2-dioxidobenzo[e][1,2,3]oxathiazin-4-yl)piperidine-4-carbonitrile (3af):




40% yield, mp 189–190 °C; **¹H NMR** (400 MHz, CDCl₃) δ 2.00–2.15 (m, 4H), 3.02–3.08 (m, 1H), 3.84–3.90 (m, 2H), 3.93–3.99 (m, 2H), 7.32–7.38 (m, 2H), 7.52 (dd, 8.0 Hz, 1.2 Hz, 1H), 7.66 (dt, 8.8 Hz, 1.6 Hz, 1H); **¹³C NMR** (100 MHz, CDCl₃) δ 163.6, 154.4, 135.5, 127.9, 125.0, 120.7, 120.0, 112.7, 46.7, 28.3, 26.0; **IR** (KBr) ν 2923, 2821, 1637, 1596, 1510, 1260, 1118, 1089, 799 cm⁻¹; **HRMS** (ESI): calcd for C₁₃H₁₄N₃O₃S [M+H]⁺ 292.0750, found 292.1138.

tert-butyl 4-(2,2-dioxidobenzo[e][1,2,3]oxathiazin-4-yl)piperazine-1-carboxylate (3ag):




60% yield, mp 171–172 °C; **1H NMR** (400 MHz, CDCl₃) δ 1.47 (s, 9H), 3.58–3.61 (m, 4H), 3.80–3.83 (m, 4H), 7.31–7.36 (m, 2H), 7.54 (dd, 8.0 Hz, 1.6 Hz, 1H), 7.64 (dt, 8.8 Hz, 1.6 Hz, 1H); **13C NMR** (100 MHz, CDCl₃) δ 163.4, 154.4, 154.3, 135.4, 128.0, 124.9, 120.6, 112.9, 80.8, 48.6, 43.1, 28.2; **IR** (KBr) ν 2925, 2824, 1693, 1611, 1588, 1534, 1467, 1421, 1365, 1251, 1162, 1017, 870, 749 cm⁻¹; **HRMS** (ESI): calcd for C₁₆H₂₂N₃O₅S [M+H]⁺ 368.1275, found 368.1687.

(4-(2,2-dioxidobenzo[e][1,2,3]oxathiazin-4-yl)piperazin-1-yl)(phenyl)methanone (3ah):



65% yield, mp 119–120 °C; **1H NMR** (400 MHz, CDCl₃) δ 3.58–4.04 (m, 8H), 7.32–7.38 (m, 2H), 7.42–7.49 (m, 5H), 7.55 (dd, 8.0 Hz, 1.2 Hz, 1H), 7.66 (dt, 8.8 Hz, 1.6 Hz, 1H); **13C NMR** (100 MHz, CDCl₃) δ 170.6, 163.6, 154.4, 135.6, 134.5, 130.4, 128.7, 128.0, 127.1, 125.0, 120.6, 112.7, 48.7, 41.9; **IR** (KBr) ν 2920, 2850, 1633, 1532, 1464, 1427, 1362, 1264, 1192, 1005, 862, 710 cm⁻¹; **HRMS** (ESI): calcd for C₁₈H₁₈N₃O₄S [M+H]⁺ 372.1013, found 372.1508.


1-(4-(2,2-dioxidobenzo[e][1,2,3]oxathiazin-4-yl)piperazin-1-yl)ethanone (3ai):



50% yield, mp 107–108 °C; **1H NMR** (400 MHz, CDCl₃) δ 2.16 (s, 3H), 3.66–3.69 (m, 2H), 3.76–3.79 (m, 2H), 3.83–3.90 (m, 4H), 7.33–7.38 (m, 2H), 7.56 (dd, 8.0 Hz, 1.6 Hz, 1H), 7.67 (dt, 8.4 Hz, 1.2 Hz, 1H); **13C NMR** (100 MHz, CDCl₃) δ 169.3, 163.6, 154.5, 135.6, 128.0, 125.0, 120.7, 112.8, 45.2, 41.0, 21.2; **IR** (KBr) ν 2925,


2823, 1645, 1587, 1534, 1425, 1357, 1275, 1190, 856, 750 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{13}\text{H}_{16}\text{N}_3\text{O}_4\text{S} [\text{M}+\text{H}]^+$ 310.0856, found 310.1267.

4-(1,1-dioxidothiomorpholino)-8-methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3bd):




77% yield, mp 300–301 °C; **1H NMR** (400 MHz, DMSO- d_6) δ 2.31 (s, 3H), 3.46 (s, 4H), 4.13 (s, 4H), 7.37 (t, 7.6 Hz, 1H), 7.68 (d, 7.6 Hz, 2H); **13C NMR** (100 MHz, DMSO- d_6) δ 163.8, 151.5, 136.8, 128.8, 126.6, 124.6, 112.5, 50.3, 46.8, 14.6; **IR** (KBr) ν 2928, 1636, 1588, 1455, 1338, 1082, 881, 755 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_5\text{S}_2 [\text{M}+\text{H}]^+$ 331.0417, found 331.0850.

4-(1,1-dioxidothiomorpholino)-7-methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3cd):




80% yield, mp 280–281 °C; **1H NMR** (400 MHz, DMSO- d_6) δ 2.43 (s, 3H), 3.45 (s, 4H), 4.13 (s, 4H), 7.28 (d, 7.6 Hz, 1H), 7.35 (s, 1H), 7.73 (d, 7.6 Hz, 1H); **13C NMR** (100 MHz, DMSO- d_6) δ 163.4, 153.4, 147.5, 128.9, 126.2, 119.9, 110.0, 50.3, 46.4, 21.1; **IR** (KBr) ν 2922, 1615, 1578, 1453, 1359, 1191, 1122, 863, 763 cm^{-1} ; **HRMS** (ESI): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_5\text{S}_2 [\text{M}+\text{H}]^+$ 331.0417, found 331.0874.

4-(1,1-dioxidothiomorpholino)-6-methylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3dd):




90% yield, mp 307–308 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 2.40 (s, 3H), 3.46 (s, 4H), 4.14 (s, 4H), 7.41 (d, 8.4 Hz, 1H), 7.60 (d, 8.4 Hz, 1H), 7.64 (s, 1H); **13C NMR** (100 MHz, DMSO-d₆) δ 163.5, 151.3, 136.4, 135.1, 128.8, 119.6, 112.4, 50.3, 46.7, 20.3; **IR** (KBr) ν 2952, 1590, 1526, 1474, 1355, 1293, 1123, 1040, 860, 749 cm⁻¹; **HRMS** (ESI): calcd for C₁₂H₁₅N₂O₅S₂ [M+H]⁺ 331.0417, found 331.0874.

4-(1,1-dioxidothiomorpholino)-6-ethylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3ed):




85% yield, mp 309–310 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 1.22 (t, 7.6 Hz, 3H), 2.71 (q, 14.8 Hz, 2H), 3.47 (s, 4H), 4.14 (s, 4H), 7.43 (d, 8.8 Hz, 1H), 7.58–7.75 (m, 2H); **13C NMR** (100 MHz, DMSO-d₆) δ 163.6, 151.4, 141.2, 135.4, 127.8, 119.7, 112.4, 50.3, 46.9, 27.3, 15.3; **IR** (KBr) ν 2923, 1638, 1531, 1485, 1355, 1175, 1124, 880 cm⁻¹; **HRMS** (ESI): calcd for C₁₃H₁₇N₂O₅S₂ [M+H]⁺ 345.0573, found 345.1026.

6-(tert-butyl)-4-(1,1-dioxidothiomorpholino)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3fd):




87% yield, mp 266–267 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 1.33 (s, 9H), 3.50 (s, 4H), 4.15 (s, 4H), 7.44 (d, 8.8 Hz, 1H), 7.72 (d, 2.4 Hz, 1H), 7.85 (dd, 8.4 Hz, 2.0 Hz, 1H); **13C NMR** (100 MHz, DMSO-d₆) δ 163.7, 151.3, 147.8, 133.2, 125.4, 119.4, 111.9, 50.2, 46.6, 34.6, 30.7; **IR** (KBr) ν 2920, 1644, 1533, 1471, 1365, 1189, 1124, 1028, 858 cm⁻¹; **HRMS** (ESI): calcd for C₁₅H₂₁N₂O₅S₂ [M+H]⁺ 373.0886, found 373.1372.

4-(1,1-dioxidothiomorpholino)-6-methoxybenzo[e][1,2,3]oxathiazine 2,2-dioxide (3gd):




78% yield, mp 280–281 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 3.46 (s, 4H), 3.85 (s, 3H), 4.16 (s, 4H), 7.28 (d, 2.8 Hz, 1H), 7.38 (dd, 8.8 Hz, 2.8 Hz, 1H), 7.47 (d, 9.2 Hz, 1H); **13C NMR** (100 MHz, DMSO-d₆) δ 163.4, 155.7, 146.9, 122.2, 120.9, 113.1, 112.6, 56.0, 50.2, 46.7; **IR** (KBr) ν 2928, 1637, 1531, 1360, 1184, 1123, 1038, 858 cm⁻¹; **HRMS** (ESI): calcd for C₁₂H₁₅N₂O₆S₂ [M+H]⁺ 347.0366, found 347.0816.

4-(1,1-dioxidothiomorpholino)-6-phenylbenzo[e][1,2,3]oxathiazine 2,2-dioxide (3hd):



72% yield, mp 308–309 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 3.50 (s, 4H), 4.21 (s, 4H), 7.44 (t, 7.2 Hz, 1H), 7.53 (t, 7.2 Hz, 2H), 7.62 (d, 8.8 Hz, 1H), 7.76 (d, 7.6 Hz, 2H), 8.08 (t, 8.4 Hz, 2H); **13C NMR** (100 MHz, DMSO-d₆) δ 163.3, 152.7, 137.9, 137.4, 134.0, 129.1, 128.2, 127.0, 120.5, 113.1, 50.2, 46.6; **IR** (KBr) ν 2926, 2821, 1644, 1598, 1455, 1120, 1021, 867 cm⁻¹; **HRMS** (ESI): calcd for C₁₇H₁₇N₂O₅S₂ [M+H]⁺ 393.0573, found 393.1084.


4-(1,1-dioxidothiomorpholino)-6-fluorobenzo[e][1,2,3]oxathiazine 2,2-dioxide (3id):



95% yield, mp 257–258 °C; **1H NMR** (400 MHz, DMSO-d₆) δ 3.46 (s, 4H), 4.15 (s, 4H), 7.63 (dd, 8.8 Hz, 4.4 Hz, 1H), 7.70–7.75 (m, 2H); **13C NMR** (100 MHz, DMSO-d₆) δ 162.5, 157.9 (q, *J*_{C-F} = 242.5 Hz), 149.5, 123.0 (q, *J*_{C-F} = 23.7 Hz), 122.0 (q, *J*_{C-F}


= 8.3 Hz), 115.7 (q, J_{C-F} = 26.3 Hz), 113.8 (q, J_{C-F} = 7.7 Hz), 50.2, 46.7; **IR** (KBr) ν 2923, 1610, 1532, 1453, 1373, 1163, 1123, 1041, 837 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₂FN₂O₅S₂ [M+H]⁺ 335.0166, found 335.0604.

6-chloro-4-(1,1-dioxidothiomorpholino)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3jd):




84% yield, mp 312–313 °C; **¹H NMR** (400 MHz, DMSO-d₆) δ 3.46 (s, 4H), 4.14 (s, 4H), 7.60 (d, 8.4 Hz, 1H), 7.89 (d, 8.4 Hz, 1H), 7.93 (s, 1H); **¹³C NMR** (100 MHz, DMSO-d₆) δ 162.2, 152.1, 135.6, 129.4, 128.5, 121.9, 114.2, 50.1, 46.4; **IR** (KBr) ν 2928, 2820, 1615, 1541, 1455, 1262, 1114, 1071, 943, 861, 733 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₂ClN₂O₅S₂ [M+H]⁺ 350.9871, found 351.0328.

6-bromo-4-(1,1-dioxidothiomorpholino)benzo[e][1,2,3]oxathiazine 2,2-dioxide (3kd):




80% yield, mp 310–311 °C; **¹H NMR** (400 MHz, DMSO-d₆) δ 3.46 (s, 4H), 4.14 (s, 4H), 7.53 (d, 8.4 Hz, 1H), 8.00 (dd, 8.8 Hz, 2.4 Hz, 1H), 8.05 (d, 2.4 Hz, 1H); **¹³C NMR** (100 MHz, DMSO-d₆) δ 162.1, 152.5, 138.4, 131.3, 122.1, 117.2, 114.6, 50.1, 46.6; **IR** (KBr) ν 2925, 1618, 1597, 1515, 1464, 1364, 1292, 1185, 889, 764 cm⁻¹; **HRMS** (ESI): calcd for C₁₁H₁₂BrN₂O₅S₂ [M+H]⁺ 394.9366, found 394.9798.

The general procedure for the late-stage modification of drug:



To a 15 mL Schlenk charged with cyclic aldimines **1a** (0.3 mmol, 55 mg), Eosin Y (6.5 mg, 0.01 mmol), DABCO (45 mg, 0.4 mmol) and desloratadine **4** (0.2 mmol, 62.2 mg) was added DSMO (2.0 mL) *via* a syringe. Then, the reaction mixture was open to the air and vigorously stirred under the irradiation of 23 W white LEDs at room temperature for 24 h. After the reaction was complete, the mixture was diluted with water (10 mL) and ethyl acetate (10 mL). The organic layer was washed with saturated brine (3×10 mL), dried anhydrous MgSO_4 , and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (petroleum ether/EtOAc as the eluent) to afford the desired products **5**.

4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)-ylidene)piperidin-1-yl)benzo[e][1,2,3]oxathiazine 2,2-dioxide (5):





white solid; 55% yield, mp 144–145 °C; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 2.48–2.53 (m, 2H), 2.61–2.68 (m, 1H), 2.78–2.92 (m, 3H), 3.29–3.42 (m, 2H), 3.56–3.62 (m, 2H), 4.03–4.12 (m, 2H), 7.10–7.17 (m, 3H), 7.19 (s, 1H), 7.28 (t, $J = 7.6$ Hz, 1H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.46 (d, $J = 7.2$ Hz, 1H), 7.56 (d, $J = 7.6$ Hz, 1H), 7.61 (t, $J = 7.6$ Hz, 1H), 8.41 (d, $J = 4.0$ Hz, 1H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 162.8, 156.2, 154.3, 146.6, 139.6, 137.8, 137.1, 135.7, 135.0, 134.6, 133.3, 133.2, 130.1, 129.0, 128.1, 126.2, 124.6, 122.5, 120.4, 113.2, 49.2, 31.5, 31.4, 30.1; **IR (KBr)** ν 2922, 1610, 1587,



1533, 1469, 1363, 1278, 1190, 1109, 993, 861, 744 cm⁻¹; **HRMS** (ESI): calcd for C₂₆H₂₃ClN₃O₃S [M+H]⁺ 492.1143, found 492.1574.



Reference:



- [1] (a) N. D. Litvinas, B. H. Brodsky, J. D. Bois, *Angew. Chem. Int. Ed.*, **2009**, *48*, 4513; (b) H. Yu, L. Zhang, Z. Yang, Z. Li, Y. Zhao, Y. Xiao, H. Guo, *J. Org. Chem.*, **2013**, *78*, 8427.



Copies of NMR spectra of the products:











































































































Crystallographic data for the product 3aa:

CCDC 1961174 contains the supplementary crystallographic data for the product **3aa**. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.




Table 1. Crystal data and structure refinement for 1.

| | | |
|-----------------------------|--|---|
| Empirical formula | $C_{11}H_{12}N_2O_4S$ | |
| Formula weight | 268.29 | |
| Temperature | 296(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal system, space group | Triclinic, P-1 | |
| Unit cell dimensions | a = 8.4413(11) Å b = 8.9170(13) Å c = 9.0986(11) Å | alpha = 95.122(5) deg. beta = 107.332(5) deg. gamma = 113.574(4) deg. |
| Volume | 581.95(13) Å ³ | |
| Z, Calculated density | 2, 1.531 Mg/m ³ | |
| Absorption coefficient | 0.287 mm ⁻¹ | |
| F(000) | 280 | |
| Crystal size | 0.23 x 0.07 x 0.06 mm | |

| | |
|-----------------------------------|---|
| Theta range for data collection | 2.83 to 27.57 deg. |
| Limiting indices | -10<=h<=10, -10<=k<=11, -11<=l<=11 |
| Reflections collected / unique | 10933 / 2643 [R(int) = 0.0247] |
| Completeness to theta = 25.03 | 98.1% |
| Refinement method | Full-matrix least-squares on F ² |
| Data / restraints / parameters | 2643 / 0 / 163 |
| Goodness-of-fit on F ² | 1.048 |
| Final R indices [I>2sigma(I)] | R1 = 0.0321, wR2 = 0.0832 |
| R indices (all data) | R1 = 0.0421, wR2 = 0.0888 |
| Largest diff. peak and hole | 0.268 and -0.413 e.A ⁻³ |